KalVista Pharmaceuticals (KALV) 10-K2024 FY Annual report

Filed: 11 Jul 24, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adhere, AFS, aim, appointment, architecture, authentication, automated, began, beneficiary, BIOSECURE, broadest, burden, CHF, Chinese, climate, compelling, conversion, coordinating, CSF, de, defense, degradation, delegated, departure, deploy, disaggregated, disagree, dollar, donut, dynamic, encryption, engineering, enrollee, firsthand, Franc, furlough, gas, GDPR, greenhouse, guide, hinder, hole, House, immutable, implicate, improperly, incomplete, inflationary, intelligence, intravenously, introduced, Ireland, ISO, Japan, Japanese, JNDA, JPMDA, JPY, justification, landscape, leadership, Leerink, NIST, Notably, older, outlined, overarching, pace, Passport, penetration, play, posture, proactively, qualitative, quantitative, quickly, recurrent, reevaluated, regular, relieve, relocate, replicate, resubmit, resubmitted, retaliation, retrospective, retrospectively, reward, routine, routinely, safeguard, safeguarding, Senate, sentiment, shift, shut, slightly, sNDA, statutorily, Stifel, subcontracted, subsidize, substandard, threat, Tokyo, UK, Underwritten, unreliable, vast, verge, verification, verify, voluntary, VP, whichever, Yen, Zug

Removed: Aid, American, back, bioavailability, bioavailable, biochemical, biologic, biology, block, Boston, calculation, cancer, closure, comparing, complicated, compound, crossover, diabetic, directed, enhance, imaging, initially, investigating, Linkbase, macular, mandated, mechanism, mg, mice, nanomolar, OfferingSM, pivotal, potency, preventing, randomized, rapid, rescue, resubstitution, Schema, selectivity, sequence, sequester, statistical, structurally, symptom, targeted, Taxonomy, Taxpayer, upstream, uptake, VAS, worsening, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

KALV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Benjamin L. Palleiko, Chief Executive Officer of KalVista Pharmaceuticals, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

•

this Annual Report on Form 10-K of the Company for the year ended April 30, 2024 (the “Report”), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

•

the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company for the periods presented therein.

Date: July 11, 2024

By:

/s/ Benjamin L. Palleiko

Benjamin L. Palleiko

Chief Executive Officer

(Principal Executive, Financial and Accounting Officer)